Current Report Filing (8-k)
February 22 2017 - 11:01AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C.20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 7, 2016
ONCOLOGIX
TECH, INC.
(Name
of Small Business Issuer as Specified in Its Charter)
|
Nevada
|
|
0-15482
|
|
86-1006416
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.Employer
Identification No.)
|
1604
W. Pinhook Rd. #200
Lafayette,
LA 70508
(Address
of principal executive offices)
(616)
977-9933
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The
Registrant’s Form 10-K, any Form 10-Q or any Form 8-K of the Registrant or any other written or oral statements made by
or on behalf of the Registrant may contain forward-looking statements that are based on management’s beliefs, assumptions,
current expectations, estimates and projections about the medical device business, and the Company itself. Statements, including
without limitation, those related to: future revenue, earnings, margins, growth, cash flows, operating measurements, tax rates
and tax benefits; expected economic returns; projected operating results, future strength of the Company; future brand positioning;
achievement of the Company vision; future marketing investments; the introduction of new lines or categories of products; future
growth or success in specific countries, categories or market sectors; capital resources and market risk are forward-looking statements.
In addition, words such as “anticipates,” “believes,” “estimates,” “expects,”
“forecasts,” “intends,” “is likely,” “plans,” “predicts,” “projects,”
“should,” “will,” variations of such words and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions
(“Risk Factors”) that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence.
Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking
statements.
Readers
are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Registrant’s views
as of the date the statement was made. The Registrant undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
ITEM
9.01 – Financial Statements and Exhibits
Series
C Preferred Stock Series.
On October 7, 2016, the Board of Directors of Oncologix Tech, Inc. (the “Company”) approved
the designation of 100,000 shares of a new series of preferred stock. The Series C Preferred Shares (“Preferred Share(s)”)
with the following rights and privileges: (i) Each Preferred Share shall have a par value of $0.001; (ii) the Preferred Share
shall not be entitled to receive any dividends; (iii) the Preferred Shares as a block shall have the voting power of 51% of the
shares of common stock and Preferred Shares taken together; (iv) the Preferred Shares are not convertible and have no redemption
rights. The complete designations are included in Exhibit 99.1. On October 7, 2016, the Board of Directors approved the issuance
of 50,000 Preferred Shares to both Michael A. Kramarz, Chief Executive Officer and Harold Halman, Chief Operating Officer in exchange
for $10,000 each of accrued salary.
ITEM
9.01 – Financial Statements and Exhibits
99.1
Series C Preferred Stock Designations
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated:
February 22, 2017
|
|
ONCOLOGIX
TECH, INC.
|
|
|
|
|
|
|
By:
|
/s/
Michael A. Kramarz
|
|
|
|
Michael
A. Kramarz, Chief Executive Officer, Chief Financial Officer
|
|
|
|
|
|
|
By:
|
/s/
Harold Halman
|
|
|
|
Harold
Halman, Chief Operating Officer,
|
Oncologix Tech (CE) (USOTC:OCLG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oncologix Tech (CE) (USOTC:OCLG)
Historical Stock Chart
From Dec 2023 to Dec 2024
